These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 38179880)

  • 21. Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis.
    Lonabaugh K; Li G; List R; Huang R; James A; Barros A; Somerville L; Albon D
    Pharmacotherapy; 2024 Mar; 44(3):231-240. PubMed ID: 38143243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults.
    Graziano S; Boldrini F; Pellicano GR; Milo F; Majo F; Cristiani L; Montemitro E; Alghisi F; Bella S; Cutrera R; Fiocchi AG; Quittner A; Tabarini P
    Chest; 2024 Apr; 165(4):800-809. PubMed ID: 37925143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor.
    Ferreira FC; Buarque CD; Lopes-Pacheco M
    Molecules; 2024 Feb; 29(4):. PubMed ID: 38398574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients.
    Klimeš F; Voskrebenzev A; Gutberlet M; Speth M; Grimm R; Dohna M; Hansen G; Wacker F; Renz DM; Dittrich AM; Vogel-Claussen J
    Eur Radiol; 2024 Jan; 34(1):80-89. PubMed ID: 37548691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of Elexacaftor/Tezacaftor/Ivacaftor.
    McParland C; Nunn M; Marras TK; Chiasson M
    J Cyst Fibros; 2024 Jan; 23(1):38-40. PubMed ID: 37076409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elexacaftor/tezacaftor/ivacaftor can rescue pancreatic function in F508del homozygous children.
    Nathan N; Thouvenin G; Dubern B; Corvol H
    Pediatr Pulmonol; 2024 Mar; 59(3):788-790. PubMed ID: 38088210
    [No Abstract]   [Full Text] [Related]  

  • 28. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
    Ramsey B; Correll CU; DeMaso DR; McKone E; Tullis E; Taylor-Cousar JL; Chu C; Volkova N; Ahluwalia N; Waltz D; Tian S; Mall MA
    Am J Respir Crit Care Med; 2024 Feb; 209(3):299-306. PubMed ID: 37890129
    [No Abstract]   [Full Text] [Related]  

  • 29. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series.
    Gramegna A; De Petro C; Leonardi G; Contarini M; Amati F; Meazza R; Carugo S; Blasi F
    J Cyst Fibros; 2022 Sep; 21(5):885-887. PubMed ID: 35450770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.
    Ramos KJ; Guimbellot JS; Valapour M; Bartlett LE; Wai TH; Goss CH; Pilewski JM; Faro A; Diamond JM;
    J Cyst Fibros; 2022 Sep; 21(5):745-752. PubMed ID: 35474016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model.
    Li D; Zhu Y; Donnelley M; Parsons D; Habgood MD; Schneider-Futschik EK
    Biomed Pharmacother; 2024 Feb; 171():116155. PubMed ID: 38232663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
    Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
    J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis?
    Merrill TB; Tyes J; Woodard TD
    Laryngoscope; 2024 Feb; 134(2):501-503. PubMed ID: 37548273
    [No Abstract]   [Full Text] [Related]  

  • 35. Persistence and evolution of
    Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
    mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
    Burgel PR; Paillasseur JL; Durieu I; Reynaud-Gaubert M; Hamidfar R; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Burnet E; Ouaalaya EH; Sogni P; Da Silva J; Martin C;
    Ann Am Thorac Soc; 2024 Jul; 21(7):1053-1064. PubMed ID: 38579175
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index.
    Patel T; McBennett K; Sankararaman S; Schindler T; Sundaram K; Minich NM; Malay S; Kutney K
    Pediatr Pulmonol; 2024 Mar; 59(3):734-742. PubMed ID: 38179878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
    Hoy SM
    Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare
    Burgel PR; Sermet-Gaudelus I; Girodon E; Kanaan R; Le Bihan J; Remus N; Ravoninjatovo B; Grenet D; Porzio M; Houdouin V; Le Clainche-Viala L; Durieu I; Nove-Josserand R; Languepin J; Coltey B; Guillaumot A; Audousset C; Chiron R; Weiss L; Fajac I; Da Silva J; Martin C;
    Eur Respir J; 2024 Jan; 63(1):. PubMed ID: 38242629
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.